Milestones
- First member-company drug in trialsDoneComplete.
- Phase 2 trials of ATX-304 (REWIRE-1 and REWIRE-2)Not yet reached.
Most important updates
- 18 Jun 2026
- 24 Feb 2026
- 11 Jul 2025
- 17 Oct 2023
- 27 Jun 2023
Current obstacles
- One disease at a timeEach aging drug must first work in one narrow disease, which makes the road to a longevity claim long.
Physics limits
- Rapamycin's target does two jobsBlocking mTORC1 extends life in mice, but long use of rapamycin also blocks mTORC2, raising blood sugar and weakening immunity. Separating the two chemically is hard.
- The energy sensor works in every tissueGenetic over-activation of AMPK thickens heart muscle, and one strong AMPK activator enlarged hearts in animals. Activators must be kept out of the heart or dosed gently.
- Mouse lifespan gains may not carry overRapamycin extends mouse lifespan by roughly 10-25% depending on dose and sex, but mice age about 30 times faster than people and no human lifespan data exists.
How it works
Model
One company per aging target
Cambrian creates affiliate companies around drivers of aging and gives them shared funding, labs and staff.
AMPK
ATX-304: turn up the energy sensor
An oral drug that switches on AMPK, the cell's low-fuel sensor, outside the brain, mimicking some effects of exercise and fasting.
mTOR
TORnado: a sharper rapamycin
Drugs that block only mTORC1, the part of the growth switch linked to longer life in animals, and spare mTORC2, which causes side effects.
Update log
Thu 18 Jun
- Major: PressTest
Tue 24 Feb
- Major: PressFunding
Fri 11 Jul 2025
- Minor: PressResearch
Tue 17 Oct 2023
- Major: PressTest
Tue 27 Jun 2023
- Minor: PressCommercial
Tue 14 Mar 2023
- Minor: PressCommercial
About Cambrian Bio
Cambrian Bio
Group of aging biotechs, rapamycin-like drugs
New York company founded by James Peyer that starts and funds a group of small biotechs, each attacking one cause of aging through a specific disease, such as better versions of the drug rapamycin.
- Founded
- 20206 yrs
- Headquarters
- United States
- Status
- Private
- Valuation
- private
- Works in
- LongevityAnti-aging drugs
- Coverage
- 1 program · 7 updateslatest 18 Jun 2026checked 25 Sep
- People
- James Peyer (opens cambrianbio.com)Co-founder and CEO